| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | VSTM | Common Stock | Award | $0 | +100,000 | +43% | $0.000000 | 331,149 | 10 Jan 2025 | Direct | F1 |
| transaction | VSTM | Common Stock | Award | $0 | +25,000 | +7.5% | $0.000000 | 356,149 | 10 Jan 2025 | Direct | F2 |
| transaction | VSTM | Common Stock | Sale | $44,896 | -8,568 | -2.4% | $5.24 | 347,581 | 13 Jan 2025 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | Restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest as to 33.3% of the RSUs on the first three anniversaries of January 10, 2025 (the "RSU Grant Date") such that the award is fully vested on January 10, 2028 (with the number of RSUs vesting on each vesting date rounded down to the nearest whole RSU, except with respect to the final vesting date on which all remaining unvested RSUs shall vest), provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. |
| F2 | The reported securities were subject to a performance RSU award that was granted on August 2, 2023. 25,000 RSUs vested on January 10, 2025 upon the Issuer's board of directors determining the performance criteria of acceptance of a new drug application for a product which contains avutometinib in combination with defactinib by the U.S. Food and Drug Administration had occurred. |
| F3 | The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of the performance-based restricted stock units. |